MoH Iraq Certification: Equilab International Expands Global Recognition in Bioequivalence Study

10 minutes ago

1 min read

We are pleased to announce that Equilab International has received recognition from the Ministry of Health (MoH) of Iraq as a research centre for Bioequivalence studies, marking another important milestone in strengthening our international regulatory recognition and global presence in Bioequivalence studies.

As a leading Bioequivalence Centre in Indonesia and Southeast Asia, this recognition further reflects Equilab’s commitment to maintaining high standards of quality, scientific integrity, and regulatory compliance while supporting pharmaceutical companies in their product development and registration across international markets

Ten employees pose in a lobby under an Equilab International sign, wearing business attire and ID badges.

The recognition by the Ministry of Health of Iraq (MoH Iraq) follows a successful inspection visit conducted at PT Equilab International in Jakarta, Indonesia, from 20–25 July 2026. During the visit, representatives from the MoH Iraq assessed Equilab’s research centre for Bioequivalence studies, including its facilities, organization, and overall study environment.

With more than 23 years of experience and more than 1,200 completed Bioequivalence studies, Equilab has established extensive expertise in supporting global pharmaceutical companies throughout the drug development and registration process worldwide. Our clinical study reports have been accepted in more than 40 countries worldwide, including the United Kingdom, Germany, Spain, Hungary, and other international markets.

Group of scientists in white lab coats pose in a bright laboratory, smiling and giving thumbs up.

As we continue to expand our global presence, Equilab remains committed to being a trusted research partner for Bioequivalence Study and Clinical Trials.